Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To describe the use of tumor necrosis factor-alpha inhibitors (TNFis) among pregnancies ending in a live birth and with a diagnosis of ankylosing spondylitis (AS), Crohn's disease (CD), juvenile idiopathic arthritis (JIA), psoriasis (PsO), psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ulcerative colitis (UC).
|
30430682 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Biologics against tumor necrosis factor (anti-TNF) have dramatically changed the management of moderate-to-severe ulcerative colitis (UC).
|
30555013 |
2019 |
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
S. boulardii treatment reduced AOM/DSS-induced UC carcinogenesis in mice, as indicated by the reduced tumor load and reduced TNF-α and IL-6 levels in vivo, as well its effects on TNF-α and IL-6 activities in vitro.
|
31694526 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Twenty-five patients with ulcerative colitis (40% anti-tumor necrosis factor α [TNFα] naive) and 28 patients with Crohn's disease (10.7% anti-TNFα naive, 53.6% having undergone at least one intestinal surgery) were enrolled.
|
30134234 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
We further demonstrated that GSK2256294, a clinical EPHX2i, reduced the production of IL2, IL12p70, IL10 and TNFα in both ulcerative colitis and Crohn's disease patient-derived explant cultures.
|
31002701 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
We aimed to compare the treatment persistence rates of infliximab versus adalimumab as first- and second-line tumor necrosis factor antagonists (anti-TNF), to identify factors potentially associated with persistence, and to evaluate reasons for withdrawal in UC patients.
|
30329067 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Searching terms were ('infliximab', OR 'anti-tumor necrosis factor', OR 'tumor necrosis factor', OR 'tumor necrosis factor alpha antibody', OR 'tumor necrosis factor antibody', OR 'IFX') and ('ulcerative colitis' OR 'UC').
|
31562896 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The long-term effects of anti-TNFα therapy in ulcerative colitis are debatable.
|
31579961 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Monoclonal antibodies (anti-tumor necrosis factor [TNF] agents, vedolizumab) are the last pharmacotherapeutic option for UC patients before surgery becomes inevitable.
|
29752633 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Aims:</b> To evaluate the cost differences between a treatment strategy including tofacitinib (TOFA) vs treatment strategies including adalimumab (ADA), golimumab (GOL), infliximab (IFX), and vedolizumab (VEDO) among all patients with moderate-to-severe ulcerative colitis (UC) (further stratified by patients naïve/exposed to tumor necrosis factor inhibitors [TNFis]).
|
31012362 |
2019 |
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Patients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease duration.
|
30625408 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, a TMDD model is proposed to describe the interaction between infliximab and TNF in UC patients.
|
31489538 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
An ability to modulate the release of the proinflammatory mediators, such as TNF-α, is an important goal in the development of therapies for the treatment of diseases, such as Crohn's disease and ulcerative colitis, associated with excessive release of inflammatory mediators.
|
30897368 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
<i>In vitro</i>, we adopted the bone marrow-derived macrophages (BMDMs) as well as BMDMs co-cultured with Caco2 cells to verify the underlying mechanisms and effects of JPQC on UC under TNF-α stimulation.
|
31210713 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
A rat UC model was induced with trinitro-benzene-sulfonic acid (TNBS), concentrations of the cytokines IL-1α, IL-6, IL-8, IL-1β, and TNF-α were significantly up-regulated and the concentrations of IL-4, IL-10, and IL-13 were significantly down-regulated compared with the control group (P < 0.05).
|
31102937 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of tumor necrosis factor alpha and increased of interleukin 10 by <i>Lactobacillus</i>: a molecular mechanism protection against TNBS-induced ulcerative colitis in chicks.
|
30821556 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The non-persistence rate of anti-TNFα therapy was 72.6% and 80.4% in the UC and CD groups, respectively, with discontinuation of medication being the most common reason in both the UC and CD groups (63.9% and 73.3%, respectively).
|
31098835 |
2019 |
Ulcerative Colitis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In the multivariate analysis, having anti-TNF drug levels above the cutoff values [odds ratio (OR) 3.1]) and having UC instead of CD (OR 4) were associated with a higher probability of having mucosal healing.
|
30426297 |
2019 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF)‑α is a central mediator of intestinal inflammation in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease.
|
29286110 |
2018 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Compared to high dose corticosteroid use, anti TNF therapy is associated with less risk for death in Crohn's disease but no statistical difference in death outcomes in ulcerative colitis.
|
29535444 |
2018 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Because anti⁻tumor necrosis factor therapy is the mainstay for the treatment of moderate-to-severe inflammatory bowel disease; including Crohn's disease and ulcerative colitis, and because testosterone therapy in hypogonadal men with chronic inflammatory conditions reduce tumor necrosis factor-alpha (TNF-α), IL-1β, and IL-6, we suggest that testosterone therapy attenuates the inflammatory process and reduces the burden of disease by mechanisms inhibiting inflammatory cytokine expression and function.
|
30558178 |
2018 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
A cohort of 149 moderately to severely active UC and CD patients who failed or showed intolerance to at least two TNF antagonists participated in a medical need program and received vedolizumab in 37 Belgian centers (April-September 2015).
|
29774158 |
2018 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease.
|
30054143 |
2018 |
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis (AS), psoriasis (Ps) and/or psoriatic arthritis (PsA) and may be administered off-label to treat disseminated granuloma annulare, systemic lupus erythematosus and systemic sclerosis.
|
28837372 |
2018 |
Ulcerative Colitis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Eight functional SNPs were associated with anti-TNF response either among patients with CD (TLR5 (rs5744174) and IFNGR2 (rs8126756)), UC (IL12B (rs3212217), IL18 (rs1946518), IFNGR1 (rs2234711), TBX21 (rs17250932) and JAK2 (rs12343867)) or in the combined cohort of patient with CD and UC (IBD) (NLRP3 (rs10754558), IL12B (rs3212217) and IFNGR1 (rs2234711)) (P<0.05).
|
28139755 |
2018 |